Rejuve.Bio and ALIS Partner to Build World's First Explainable, AGI-Native Clinical Co-Pilot for Longevity Medicine.
Built on the AGI platform Hyperon, ALIS delivers mortality-validated, traceable clinical intelligence, designed to serve 10,000+ clinics and over 1 million patients globally.
Rejuve.Bio , a longevity biotechnology company incubated within the SingularityNET ecosystem , today announced a strategic partnership with ALIS (Advanced Longevity Intelligence System) to develop the world's first AGI-native clinical co-pilot for longevity medicine. The platform will support longevity-medicine clinics around the world, helping patients live longer, healthier lives.
ALIS is a clinical support platform powered by Hyperon, a neural-symbolic AGI framework. It will ingest biomarkers (including genomics, epigenetics, clinical lab data, and wearables) and deliver ranked, evidence-weighted intervention suggestions that are fully explainable and traceable to their source data.
ALIS is built on an entirely different architecture to other clinical AI tools. Using Probabilistic Logic Networks (PLNs) instead of neural nets means ALIS does not function as a black box. Every suggestion includes a complete reasoning chain, enabling clinicians to audit, interrogate, and defend every output. This provides explainability, future-proofing it against emerging regulations.
Conventional neural-network AI ingests data, processes it through a series of learned transformations, and produces an output. The transformations are opaque, and the reasoning isn't stored. If you ask the system why it produced its output, it cannot tell you; it does not know. It pattern-matched; it did not reason. In medicine, this is a regulatory liability. Platforms built on black-box architectures have a regulatory reckoning coming. Hyperon reasons. It is fully transparent.
A clinician can click on any ALIS suggestion and see the whole reasoning stack: which biomarkers triggered it, what the evidence base is, how confident the system is, and - importantly - what missing data would change the picture. These architectural choices put ALIS ahead of emerging regulatory requirements. The EU AI Act (fully applicable for high-risk healthcare categories since 2025) and the FDA's evolving 'SaMD' framework both mandate transparency and explainability for clinical AI. Platforms built on opaque models face compliance risk; ALIS is structurally compliant today.
ALIS is built on decades of peer-reviewed science, it is not a startup idea. The aging research behind ALIS is mortality-validated and comes from two of the world's most cited scientists in longevity medicine:
Brian Kennedy is co-founder & scientific director of ALIS, co-creator of the LinAge clock, distinguished professor at NUS Medicine, and one of the world's most cited researchers in the biology of aging, with over 42,000 citations. Associate Prof. Jan Gruber is based at Yale-NUS and NUS Medicine, where he is distinguished professor. He is co-creator of the LinAge clock, and director of research at ALIS. The LinAge clock and the Intervention Atlas are field-tested, evidence-based models at the forefront of longevity science:
LinAge clock : provides a biological age score with clinical validation. Unlike conventional biological age measures, the LinAge clock is trained on actual mortality outcomes - not just chronological patterns. When ALIS reports that a patient's biological age is elevated, that is a mortality-validated signal.
Intervention Atlas : The Intervention Atlas takes each patient's aging profile - expressed as Principal Components that capture composite, multi-dimensional patterns across their full biomarker panel - and it maps that to a ranked set of clinical interventions, bridging the gap from insight to intervention.
The ALIS platform is built on three interconnected technical layers:
The Atomspace knowledge graph stores the entire Atomspace and Intervention Atlas as a queryable, updatable metagraph (a 'graph of graphs' consisting of metadata for a knowledge graph, defining the structure, schema, and semantics of the relationships between entities). Every biomarker-to-intervention link carries a confidence value and evidence quality rating. When you bake a cake, you must put in the correct ingredients at the start; you can't change it halfway through. When you make a stew, you can add things at any time. Neural networks are like baking a cake. The Atomspace is like making a stew. The Atomspace updates itself at the node level the moment new evidence is published - with no retraining and no lag. Probabilistic Logic Networks (PLN) weight every inference by the strength of its supporting evidence. For example, it distinguishes Randomized Controlled Trials from observational studies. It can reason - not hallucinate - when patient data is incomplete. The PLN provides a traceable chain of reasoning - every suggestion linked back to the specific biomarkers that drove it, the inference path through the Atomspace, and the confidence level of the conclusion. It is robust to incomplete sets of data - and in the real world sets of data are always incomplete. None of the reasoning sophistication described above matters at clinical scale without the processing power to execute it across thousands of clinics and millions of patient records in real time: that is what MORK provides. MORK is a blazing-fast hypergraph processing kernel for Hyperon.The MORK processing kernel accelerates critical operations by orders of magnitude, allowing ALIS to handle millions of patient records feasible. "The longevity field has generated extraordinary science, but the tools clinicians have to put it into practice have lagged a decade behind," said Kennedy Schaal, CEO of Rejuve.Bio. "We are not launching another dashboard. We are deploying the only AI architecture that can handle the complexity of biological aging and explain its reasoning at the same time. That is the difference between a wellness feature and a clinical standard."
The longevity medicine field is generating an unprecedented volume of data. Epigenetic clocks, multi-omics panels, wearable biometrics, genomic sequences, and decades of longitudinal clinical observations. There has never been more information about patients' biological aging trajectories. But the data have outpaced the tools clinicians have to use it. What has been missing is a translation layer that can take a patient's full biological profile and produce something a clinician can act on with confidence. With ALIS, that gap is closed.
The partnership brings together two teams with proven track records in AI and longevity medicine. Rejuve.Bio builds and maintains the technology stack: data ingestion and normalisation, the Hyperon-powered intelligence engine, the client-facing dashboard, the practitioner and admin console, the reporting engine, and the AWS cloud architecture ready to scale from ten clinics to ten thousand. The company was incubated within the SingularityNET ecosystem - the organisation founded by Dr. Ben Goertzel that created Hyperon, one of the most advanced artificial general intelligence frameworks in existence.
ALIS contributes the scientific methodology - including the mortality-validated LinAge clock and the Intervention Atlas - and client acquisition and strategic partnerships through its clinical network courtesy Longevity Summit Dublin founder Martin O'Dea.
Early clinic access for the ALIS platform is open now, with phased deployment prioritising longevity clinics in Singapore, Ireland, the UK, and the EU. The platform is HIPAA-ready, GDPR-compliant, and architected for an ISO 27001 certification pathway.
The infrastructure is HIPAA-ready, GDPR-compliant, and built with role-based access control and full audit logging from day one. Data residency options are available for EU, UK, and Singapore deployments. The platform is architected for an ISO 27001 certification pathway as ALIS scales.
All data connections - lab panels, wearable providers, genetic testing companies, EHR systems - are handled via API integrations with a normalisation layer that maps every input to a unified ALIS schema. CSV and PDF manual upload is available for early-phase onboarding.
ABOUT REJUVE.BIO
Rejuve.Bio is a longevity biotechnology company deploying neural-symbolic AGI to translate complex biological data into actionable clinical intelligence. Incubated within the SingularityNET ecosystem and powered by Hyperon, the company has deployed longevity AI across 370+ biomarkers spanning genomics, epigenetics, wearables, and clinical lab data. rejuve.bio
ABOUT ALIS
ALIS is an AI-powered clinical co-pilot for longevity medicine, translating biological aging data into ranked, evidence-weighted clinical intelligence. Co-founded by Prof. Brian Kennedy (NUS Medicine) and Martin O'Dea (Longevity Summit Dublin), ALIS is built on the mortality-validated LinAge clock and the Intervention Atlas methodology. alishealth.ai
